Cosibelimab-Ipdl Application Scope

Treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation.

Cosibelimab-Ipdl Characteristics

Ingredients: Active ingredient: Cosibelimab-ipdl, a fully human IgG1 monoclonal antibody targeting PD-L1.
Properties: Blocks the interaction between PD-L1 and its receptors PD-1 and B7.1, enhancing anti-tumor immune response. Also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Packaging Specification: Supplied as a solution for intravenous infusion.
Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Expiry Date: Refer to the product labeling for specific expiration information.
Executive Standard: Approved by the U.S. Food and Drug Administration (FDA).
Approval Number: Biologics License Application (BLA) number 761297.
Date of Revision: December 2024.
Manufacturer: Checkpoint Therapeutics, Inc.

Guidelines for the Use of Cosibelimab-Ipdl

Dosage and Administration: Administer 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
Adverse Reactions:
- Common (≥10%): Fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, urinary tract infection.
- Serious: Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, and others.
Contraindications: None listed. However, caution is advised in patients with a history of severe hypersensitivity reactions to monoclonal antibodies.
Precautions:
- Monitor for signs of immune-mediated adverse reactions.
- Evaluate liver enzymes, creatinine, and thyroid function tests at baseline and periodically during treatment.
- Withhold or permanently discontinue treatment based on the severity of adverse reactions.

Cosibelimab-Ipdl Interactions

Drug Interactions: No formal drug interaction studies have been conducted. However, concomitant use with immunosuppressive agents may diminish the efficacy of cosibelimab-ipdl.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.